Abiopharma

🔍 Spignesi Robert G. Jr. (Director)

Company: RAPID MICRO BIOSYSTEMS, INC. (RPID)

Report Date: 2026-05-29

Detailed Transactions and Holdings:

• Acquired 12,787 shares of Class A Common Stock at $1.955 per share (Direct)
  Date: 2026-05-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,190,571.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 12,787 shares of Series A Warrant (right to buy) at $1.955 per share (Derivative)
  Date: 2026-05-29 | Code: A | Expires: 2027-05-29 | Exercise: 2026-11-29 | equity_swap_involved: 0 | shares_owned_after: 12,787.00 | transaction_form_type: 4 | Footnotes: F1, F1, F3
• Acquired 12,787 shares of Series B Warrant (right to buy) at $2.34 per share (Derivative)
  Date: 2026-05-29 | Code: A | Expires: 2031-05-29 | Exercise: 2026-11-29 | equity_swap_involved: 0 | shares_owned_after: 12,787.00 | transaction_form_type: 4 | Footnotes: F1, F1, F3

Footnotes:

• F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
• F2: Includes 7,936 shares acquired under the Rapid Micro Biosystems, Inc. employee stock purchase plan on March 13, 2026.
• F3: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.